1. Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Issue 5 (13th October 2022) Authors: Joseph‐Mathurin, Nelly; Llibre‐Guerra, Jorge J.; Li, Yan; McCullough, Austin A.; Hofmann, Carsten; Wojtowicz, Jakub; Park, Ethan; Wang, Guoqiao; Preboske, Gregory M.; Wang, Qing; Gordon, Brian A.; Chen, Charles D.; Flores, Shaney; Aggarwal, Neelum T.; Berman, Sarah B.; Bird, Thomas D.; Black, San... Journal: Annals of neurology Issue: Volume 92:Issue 5(2022) Page Start: 729 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Baseline participant characteristics of GRADUATION: a study to evaluate once‐weekly subcutaneous administration of gantenerumab. (20th December 2022) Authors: Boess, Frank; Lane, Christopher; Scelsi, Marzia A.; Delmar, Paul; Hofmann, Carsten; Tonietto, Matteo; Klein, Gregory; Kerchner, Geoffrey A.; Baudler, Monika; Doody, Rachelle S. Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 10 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Characterization of amyloid‐related imaging abnormality in the DIAN‐TU‐001 trial. (31st December 2021) Authors: Joseph‐Mathurin, Nelly; Llibre‐Guerra, Jorge J; McCullough, Austin A.; Li, Yan; Hofmann, Carsten; Wojtowicz, Jakub; Wang, Qing; Wang, Guoqiao; Gordon, Brian A.; Chen, Charles D.; Brooks, William S.; Gauthier, Serge; Holdridge, Karen C.; Hsiung, Ging‐Yuek Robin; Jack, Clifford R.; Klein, Gregory; ... Journal: Alzheimer's & dementia Issue: Volume 17:(2021)Supplement 1 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Disease Modeling and Model‐Based Meta‐Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease. Issue 4 (28th February 2022) Authors: Retout, Sylvie; Gieschke, Ronald; Serafin, Daniel; Weber, Cornelia; Frey, Nicolas; Hofmann, Carsten Journal: Clinical pharmacology & therapeutics Issue: Volume 111:Issue 4(2022) Page Start: 857 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DT‐01‐02: CONTINUED LARGE AMYLOID PET REDUCTIONS AT 36 MONTHS IN THE GANTENERUMAB OPEN‐LABEL EXTENSION STUDIES. (1st July 2019) Authors: Klein, Gregory; Delmar, Paul; Kerchner, Geoffrey A.; Hofmann, Carsten; Abi-Saab, Danielle; Ristic, Smiljana; Rehal, Sunita; Voyle, Nicola; Baudler, Monika; Fontoura, Paulo; Doody, Rachelle Journal: Alzheimer's & dementia Issue: Volume 15:Supplement 7(2019)Part 28 Page Start: P1484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Issue 1 (3rd November 2022) Authors: Wang, Guoqiao; Li, Yan; Xiong, Chengjie; McDade, Eric; Clifford, David B.; Mills, Susan L.; Santacruz, Anna M.; Aschenbrenner, Andrew J.; Hassenstab, Jason; Benzinger, Tammie L.S.; Gordon, Brian A.; Fagan, Anne M.; Coalier, Kelley A.; Libre‐Guerra, Jorge J.; McCullough, Austin; Joseph‐Mathurin, N... Journal: Alzheimer's & dementia Issue: Volume 14:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Graduation study design: Evaluation of once‐weekly subcutaneous administration of gantenerumab on brain amyloid load. (31st December 2021) Authors: Boess, Frank; Sakaoka, Shunsuke; Abi‐Saab, Danielle; Scelsi, Marzia Antonella; Delmar, Paul; Hofmann, Carsten; Klein, Gregory; Baudler, Monika; Doody, Rachelle; Kerchner, Geoffrey A Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model. Issue 1 (6th June 2022) Authors: Aldea, Roxana; Grimm, Hans Peter; Gieschke, Ronald; Hofmann, Carsten; Lott, Dominik; Bullain, Szofia; Delmar, Paul; Klein, Gregory; Lyons, Marco; Piazza, Fabrizio; Carare, Roxana O.; Mazer, Norman A. Journal: Alzheimer's & dementia Issue: Volume 8:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment. (20th December 2022) Authors: Mazer, Norman A; Hofmann, Carsten; Lott, Dominik; Gieschke, Ronald; Klein, Gregory; Boess, Frank; Grimm, Hans Peter; Kerchner, Geoffrey A.; Baudler, Monika; Smith, Janice; Schobel, Scott; Doody, Rachelle S. Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 3 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. O1‐09‐02: THE EFFECT OF LOW DOSES OF GANTENERUMAB ON AMYLOID AND TAU BIOMARKERS IN CEREBROSPINAL FLUID (CSF) IN THE MARGUERITE ROAD STUDY. (1st July 2006) Authors: Voyle, Nicola; Abi-Saab, Danielle; Klein, Gregory; Hofmann, Carsten; Delmar, Paul; Pross, Nathalie; Andjelkovic, Mirjana; Milosavljevic-Ristic, Smiljana; Martenyi, Ferenc; Fontoura, Paulo; Doody, Rachelle Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7S(2018)Part 4 Page Start: P240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗